HapticV1, PascalFrancis, Corpus, bibRecord, 000B40

Outcome of phacoemulsification in patients with uveitis

Identifieur interne : 000B40 ( PascalFrancis/Corpus ); précédent : 000B39; suivant : 000B41

Outcome of phacoemulsification in patients with uveitis

Auteurs : M. A. Elgohary ; P. J. Mccluskey ; H. M. A. Towler ; N. Okhravi ; R. P. Singh ; R. Obikpo ; S. S. Lightman

Source :

British journal of ophthalmology [ 0007-1161 ] ; 2007.

RBID : Pascal:07-0303695

Descripteurs français

Pascal (Inist)
- Uvéite, Pronostic, Evolution, Phacoémulsification, Chirurgie, Homme, Ophtalmologie, Traitement.

English descriptors

KwdEn :
- Evolution, Human, Ophthalmology, Phacoemulsification, Prognosis, Surgery, Treatment, Uveitis.

Abstract

Aims: To examine the visual outcome and identify risk factors for postoperative uveitis, macular oedema and neodymium-doped yttrium aluminium garnet (Nd:YAG) capsulotomy after phacoemulsification and intraocular lens (IOL) implantation in patients with uveitis. Method: This is a retrospective review of the medical records of 101 eyes of 101 patients. One eye was randomly selected for inclusion in patients who had bilateral surgery. Patients with juvenile arthritis, keratouveitis and lymphoma-associated uveitis were excluded. Results: At the first postoperative and final visits, visual acuity was significantly better (p<0.001), and 64.4% and 71.3% of patients, respectively, had achieved ≥2 Snellen's lines of visual improvement. The cumulative probability of doubling of the visual angle was 52% over 6 years of follow-up, and this occurred at a higher rate in the presence of preoperative retinal or optic nerve lesions (HR (95% Cl) 4.49 (1.41 to 14.29)). Within 3 months after operation, uveitis was more likely to develop in female patients (OR (95% Cl) 6.21 (1.41 to 27.43)) and in the presence of significant intraoperative posterior synechiae (OR (95% Cl) 8.43 (1.09 to 65.41)); macular oedema was more likely to develop in patients who developed postoperative uveitis (OR (95% Cl) 7.45 (1.63 to 34.16)). Nd:YAG capsulotomy occurred at a higher rate in patients aged ≤5 years (HR (95% Cl) 2.28 (1.06, 4.93)) and in those with hydrogel lOLs (HR (95% Cl) 3.71 (1.04 to 13.20)), and occurred at a lower rate in patients who had prophylactic systemic corticosteroids (HR (95% Cl) 0.25 (0.11 to 0.59)), with plate-haptic silicone lOLs (HR (95% Cl) 0.23 (0.08 to 0.64)) and three-piece silicone lOLs (HR (95% Cl) 0.19 (0.05 to 0.74)) in comparison to those with polymethylmethacrylate lOLs. Conclusion: Most patients with uveitis achieve improved visual acuity after phacoemulsification, but an increasing rate of visual loss is observed in those with pre-existent macular or optic nerve lesions. Identifying patients who are at risk of postoperative complications should help in patient counselling and to pre-empt these complications by using preoperative prophylactic corticosteroids, careful IOL selection and postoperative intensive corticosteroids.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0007-1161`
A02	`01`			`@0 BJOPAL`
A03		`1`		`@0 Br. j. ophthalmol.`
A05				`@2 91`
A06				`@2 7`
A08	`01`	`1`	`ENG`	`@1 Outcome of phacoemulsification in patients with uveitis`
A11	`01`	`1`		`@1 ELGOHARY (M. A.)`
A11	`02`	`1`		`@1 MCCLUSKEY (P. J.)`
A11	`03`	`1`		`@1 TOWLER (H. M. A.)`
A11	`04`	`1`		`@1 OKHRAVI (N.)`
A11	`05`	`1`		`@1 SINGH (R. P.)`
A11	`06`	`1`		`@1 OBIKPO (R.)`
A11	`07`	`1`		`@1 LIGHTMAN (S. S.)`
A14	`01`			`@1 Moortields Eye Hospital @2 London @3 GBR @Z 1 aut. @Z 4 aut. @Z 7 aut.`
A14	`02`			`@1 Tanta University Ophthalmology Hospital @2 Tanta @3 EGY @Z 1 aut.`
A14	`03`			`@1 Royal Prince Alfred Hospital @2 Sydney, New South Wales @3 AUS @Z 2 aut. @Z 5 aut.`
A14	`04`			`@1 Whipps Cross University Hospital @2 London @3 GBR @Z 3 aut. @Z 6 aut.`
A20				`@1 916-921`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 1015 @5 354000149408200220`
A44				`@0 0000 @1 © 2007 INIST-CNRS. All rights reserved.`
A45				`@0 36 ref.`
A47	`01`	`1`		`@0 07-0303695`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 British journal of ophthalmology`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Aims: To examine the visual outcome and identify risk factors for postoperative uveitis, macular oedema and neodymium-doped yttrium aluminium garnet (Nd:YAG) capsulotomy after phacoemulsification and intraocular lens (IOL) implantation in patients with uveitis. Method: This is a retrospective review of the medical records of 101 eyes of 101 patients. One eye was randomly selected for inclusion in patients who had bilateral surgery. Patients with juvenile arthritis, keratouveitis and lymphoma-associated uveitis were excluded. Results: At the first postoperative and final visits, visual acuity was significantly better (p<0.001), and 64.4% and 71.3% of patients, respectively, had achieved ≥2 Snellen's lines of visual improvement. The cumulative probability of doubling of the visual angle was 52% over 6 years of follow-up, and this occurred at a higher rate in the presence of preoperative retinal or optic nerve lesions (HR (95% Cl) 4.49 (1.41 to 14.29)). Within 3 months after operation, uveitis was more likely to develop in female patients (OR (95% Cl) 6.21 (1.41 to 27.43)) and in the presence of significant intraoperative posterior synechiae (OR (95% Cl) 8.43 (1.09 to 65.41)); macular oedema was more likely to develop in patients who developed postoperative uveitis (OR (95% Cl) 7.45 (1.63 to 34.16)). Nd:YAG capsulotomy occurred at a higher rate in patients aged ≤5 years (HR (95% Cl) 2.28 (1.06, 4.93)) and in those with hydrogel lOLs (HR (95% Cl) 3.71 (1.04 to 13.20)), and occurred at a lower rate in patients who had prophylactic systemic corticosteroids (HR (95% Cl) 0.25 (0.11 to 0.59)), with plate-haptic silicone lOLs (HR (95% Cl) 0.23 (0.08 to 0.64)) and three-piece silicone lOLs (HR (95% Cl) 0.19 (0.05 to 0.74)) in comparison to those with polymethylmethacrylate lOLs. Conclusion: Most patients with uveitis achieve improved visual acuity after phacoemulsification, but an increasing rate of visual loss is observed in those with pre-existent macular or optic nerve lesions. Identifying patients who are at risk of postoperative complications should help in patient counselling and to pre-empt these complications by using preoperative prophylactic corticosteroids, careful IOL selection and postoperative intensive corticosteroids.
C02	`01`	`X`		`@0 002B09N`
C02	`02`	`X`		`@0 002B09F`
C03	`01`	`X`	`FRE`	`@0 Uvéite @5 01`
C03	`01`	`X`	`ENG`	`@0 Uveitis @5 01`
C03	`01`	`X`	`SPA`	`@0 Uveitis @5 01`
C03	`02`	`X`	`FRE`	`@0 Pronostic @5 02`
C03	`02`	`X`	`ENG`	`@0 Prognosis @5 02`
C03	`02`	`X`	`SPA`	`@0 Pronóstico @5 02`
C03	`03`	`X`	`FRE`	`@0 Evolution @5 03`
C03	`03`	`X`	`ENG`	`@0 Evolution @5 03`
C03	`03`	`X`	`SPA`	`@0 Evolución @5 03`
C03	`04`	`X`	`FRE`	`@0 Phacoémulsification @5 05`
C03	`04`	`X`	`ENG`	`@0 Phacoemulsification @5 05`
C03	`04`	`X`	`SPA`	`@0 Facoemulsificación @5 05`
C03	`05`	`X`	`FRE`	`@0 Chirurgie @5 06`
C03	`05`	`X`	`ENG`	`@0 Surgery @5 06`
C03	`05`	`X`	`SPA`	`@0 Cirugía @5 06`
C03	`06`	`X`	`FRE`	`@0 Homme @5 08`
C03	`06`	`X`	`ENG`	`@0 Human @5 08`
C03	`06`	`X`	`SPA`	`@0 Hombre @5 08`
C03	`07`	`X`	`FRE`	`@0 Ophtalmologie @5 09`
C03	`07`	`X`	`ENG`	`@0 Ophthalmology @5 09`
C03	`07`	`X`	`SPA`	`@0 Oftalmología @5 09`
C03	`08`	`X`	`FRE`	`@0 Traitement @5 25`
C03	`08`	`X`	`ENG`	`@0 Treatment @5 25`
C03	`08`	`X`	`SPA`	`@0 Tratamiento @5 25`
C07	`01`	`X`	`FRE`	`@0 Oeil pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Eye disease @5 37`
C07	`01`	`X`	`SPA`	`@0 Ojo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Uvée pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Uvea disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Uvea patología @5 38`
N21				`@1 197`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 07-0303695 INIST
ET :	Outcome of phacoemulsification in patients with uveitis
AU :	ELGOHARY (M. A.); MCCLUSKEY (P. J.); TOWLER (H. M. A.); OKHRAVI (N.); SINGH (R. P.); OBIKPO (R.); LIGHTMAN (S. S.)
AF :	Moortields Eye Hospital/London/Royaume-Uni (1 aut., 4 aut., 7 aut.); Tanta University Ophthalmology Hospital/Tanta/Egypte (1 aut.); Royal Prince Alfred Hospital/Sydney, New South Wales/Australie (2 aut., 5 aut.); Whipps Cross University Hospital/London/Royaume-Uni (3 aut., 6 aut.)
DT :	Publication en série; Niveau analytique
SO :	British journal of ophthalmology; ISSN 0007-1161; Coden BJOPAL; Royaume-Uni; Da. 2007; Vol. 91; No. 7; Pp. 916-921; Bibl. 36 ref.
LA :	Anglais
EA :	Aims: To examine the visual outcome and identify risk factors for postoperative uveitis, macular oedema and neodymium-doped yttrium aluminium garnet (Nd:YAG) capsulotomy after phacoemulsification and intraocular lens (IOL) implantation in patients with uveitis. Method: This is a retrospective review of the medical records of 101 eyes of 101 patients. One eye was randomly selected for inclusion in patients who had bilateral surgery. Patients with juvenile arthritis, keratouveitis and lymphoma-associated uveitis were excluded. Results: At the first postoperative and final visits, visual acuity was significantly better (p<0.001), and 64.4% and 71.3% of patients, respectively, had achieved ≥2 Snellen's lines of visual improvement. The cumulative probability of doubling of the visual angle was 52% over 6 years of follow-up, and this occurred at a higher rate in the presence of preoperative retinal or optic nerve lesions (HR (95% Cl) 4.49 (1.41 to 14.29)). Within 3 months after operation, uveitis was more likely to develop in female patients (OR (95% Cl) 6.21 (1.41 to 27.43)) and in the presence of significant intraoperative posterior synechiae (OR (95% Cl) 8.43 (1.09 to 65.41)); macular oedema was more likely to develop in patients who developed postoperative uveitis (OR (95% Cl) 7.45 (1.63 to 34.16)). Nd:YAG capsulotomy occurred at a higher rate in patients aged ≤5 years (HR (95% Cl) 2.28 (1.06, 4.93)) and in those with hydrogel lOLs (HR (95% Cl) 3.71 (1.04 to 13.20)), and occurred at a lower rate in patients who had prophylactic systemic corticosteroids (HR (95% Cl) 0.25 (0.11 to 0.59)), with plate-haptic silicone lOLs (HR (95% Cl) 0.23 (0.08 to 0.64)) and three-piece silicone lOLs (HR (95% Cl) 0.19 (0.05 to 0.74)) in comparison to those with polymethylmethacrylate lOLs. Conclusion: Most patients with uveitis achieve improved visual acuity after phacoemulsification, but an increasing rate of visual loss is observed in those with pre-existent macular or optic nerve lesions. Identifying patients who are at risk of postoperative complications should help in patient counselling and to pre-empt these complications by using preoperative prophylactic corticosteroids, careful IOL selection and postoperative intensive corticosteroids.
CC :	002B09N; 002B09F
FD :	Uvéite; Pronostic; Evolution; Phacoémulsification; Chirurgie; Homme; Ophtalmologie; Traitement
FG :	Oeil pathologie; Uvée pathologie
ED :	Uveitis; Prognosis; Evolution; Phacoemulsification; Surgery; Human; Ophthalmology; Treatment
EG :	Eye disease; Uvea disease
SD :	Uveitis; Pronóstico; Evolución; Facoemulsificación; Cirugía; Hombre; Oftalmología; Tratamiento
LO :	INIST-1015.354000149408200220
ID :	07-0303695

Links to Exploration step

Pascal:07-0303695

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Outcome of phacoemulsification in patients with uveitis</title>
<author><name sortKey="Elgohary, M A" sort="Elgohary, M A" uniqKey="Elgohary M" first="M. A." last="Elgohary">M. A. Elgohary</name>
<affiliation><inist:fA14 i1="01"><s1>Moortields Eye Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Tanta University Ophthalmology Hospital</s1>
<s2>Tanta</s2>
<s3>EGY</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mccluskey, P J" sort="Mccluskey, P J" uniqKey="Mccluskey P" first="P. J." last="Mccluskey">P. J. Mccluskey</name>
<affiliation><inist:fA14 i1="03"><s1>Royal Prince Alfred Hospital</s1>
<s2>Sydney, New South Wales</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Towler, H M A" sort="Towler, H M A" uniqKey="Towler H" first="H. M. A." last="Towler">H. M. A. Towler</name>
<affiliation><inist:fA14 i1="04"><s1>Whipps Cross University Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Okhravi, N" sort="Okhravi, N" uniqKey="Okhravi N" first="N." last="Okhravi">N. Okhravi</name>
<affiliation><inist:fA14 i1="01"><s1>Moortields Eye Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Singh, R P" sort="Singh, R P" uniqKey="Singh R" first="R. P." last="Singh">R. P. Singh</name>
<affiliation><inist:fA14 i1="03"><s1>Royal Prince Alfred Hospital</s1>
<s2>Sydney, New South Wales</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Obikpo, R" sort="Obikpo, R" uniqKey="Obikpo R" first="R." last="Obikpo">R. Obikpo</name>
<affiliation><inist:fA14 i1="04"><s1>Whipps Cross University Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lightman, S S" sort="Lightman, S S" uniqKey="Lightman S" first="S. S." last="Lightman">S. S. Lightman</name>
<affiliation><inist:fA14 i1="01"><s1>Moortields Eye Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0303695</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0303695 INIST</idno>
<idno type="RBID">Pascal:07-0303695</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B40</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Outcome of phacoemulsification in patients with uveitis</title>
<author><name sortKey="Elgohary, M A" sort="Elgohary, M A" uniqKey="Elgohary M" first="M. A." last="Elgohary">M. A. Elgohary</name>
<affiliation><inist:fA14 i1="01"><s1>Moortields Eye Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Tanta University Ophthalmology Hospital</s1>
<s2>Tanta</s2>
<s3>EGY</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mccluskey, P J" sort="Mccluskey, P J" uniqKey="Mccluskey P" first="P. J." last="Mccluskey">P. J. Mccluskey</name>
<affiliation><inist:fA14 i1="03"><s1>Royal Prince Alfred Hospital</s1>
<s2>Sydney, New South Wales</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Towler, H M A" sort="Towler, H M A" uniqKey="Towler H" first="H. M. A." last="Towler">H. M. A. Towler</name>
<affiliation><inist:fA14 i1="04"><s1>Whipps Cross University Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Okhravi, N" sort="Okhravi, N" uniqKey="Okhravi N" first="N." last="Okhravi">N. Okhravi</name>
<affiliation><inist:fA14 i1="01"><s1>Moortields Eye Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Singh, R P" sort="Singh, R P" uniqKey="Singh R" first="R. P." last="Singh">R. P. Singh</name>
<affiliation><inist:fA14 i1="03"><s1>Royal Prince Alfred Hospital</s1>
<s2>Sydney, New South Wales</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Obikpo, R" sort="Obikpo, R" uniqKey="Obikpo R" first="R." last="Obikpo">R. Obikpo</name>
<affiliation><inist:fA14 i1="04"><s1>Whipps Cross University Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lightman, S S" sort="Lightman, S S" uniqKey="Lightman S" first="S. S." last="Lightman">S. S. Lightman</name>
<affiliation><inist:fA14 i1="01"><s1>Moortields Eye Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">British journal of ophthalmology</title>
<title level="j" type="abbreviated">Br. j. ophthalmol.</title>
<idno type="ISSN">0007-1161</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">British journal of ophthalmology</title>
<title level="j" type="abbreviated">Br. j. ophthalmol.</title>
<idno type="ISSN">0007-1161</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Evolution</term>
<term>Human</term>
<term>Ophthalmology</term>
<term>Phacoemulsification</term>
<term>Prognosis</term>
<term>Surgery</term>
<term>Treatment</term>
<term>Uveitis</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Uvéite</term>
<term>Pronostic</term>
<term>Evolution</term>
<term>Phacoémulsification</term>
<term>Chirurgie</term>
<term>Homme</term>
<term>Ophtalmologie</term>
<term>Traitement</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Aims: To examine the visual outcome and identify risk factors for postoperative uveitis, macular oedema and neodymium-doped yttrium aluminium garnet (Nd:YAG) capsulotomy after phacoemulsification and intraocular lens (IOL) implantation in patients with uveitis. Method: This is a retrospective review of the medical records of 101 eyes of 101 patients. One eye was randomly selected for inclusion in patients who had bilateral surgery. Patients with juvenile arthritis, keratouveitis and lymphoma-associated uveitis were excluded. Results: At the first postoperative and final visits, visual acuity was significantly better (p<0.001), and 64.4% and 71.3% of patients, respectively, had achieved ≥2 Snellen's lines of visual improvement. The cumulative probability of doubling of the visual angle was 52% over 6 years of follow-up, and this occurred at a higher rate in the presence of preoperative retinal or optic nerve lesions (HR (95% Cl) 4.49 (1.41 to 14.29)). Within 3 months after operation, uveitis was more likely to develop in female patients (OR (95% Cl) 6.21 (1.41 to 27.43)) and in the presence of significant intraoperative posterior synechiae (OR (95% Cl) 8.43 (1.09 to 65.41)); macular oedema was more likely to develop in patients who developed postoperative uveitis (OR (95% Cl) 7.45 (1.63 to 34.16)). Nd:YAG capsulotomy occurred at a higher rate in patients aged ≤5 years (HR (95% Cl) 2.28 (1.06, 4.93)) and in those with hydrogel lOLs (HR (95% Cl) 3.71 (1.04 to 13.20)), and occurred at a lower rate in patients who had prophylactic systemic corticosteroids (HR (95% Cl) 0.25 (0.11 to 0.59)), with plate-haptic silicone lOLs (HR (95% Cl) 0.23 (0.08 to 0.64)) and three-piece silicone lOLs (HR (95% Cl) 0.19 (0.05 to 0.74)) in comparison to those with polymethylmethacrylate lOLs. Conclusion: Most patients with uveitis achieve improved visual acuity after phacoemulsification, but an increasing rate of visual loss is observed in those with pre-existent macular or optic nerve lesions. Identifying patients who are at risk of postoperative complications should help in patient counselling and to pre-empt these complications by using preoperative prophylactic corticosteroids, careful IOL selection and postoperative intensive corticosteroids.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0007-1161</s0>
</fA01>
<fA02 i1="01"><s0>BJOPAL</s0>
</fA02>
<fA03 i2="1"><s0>Br. j. ophthalmol.</s0>
</fA03>
<fA05><s2>91</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Outcome of phacoemulsification in patients with uveitis</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ELGOHARY (M. A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MCCLUSKEY (P. J.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>TOWLER (H. M. A.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>OKHRAVI (N.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SINGH (R. P.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>OBIKPO (R.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LIGHTMAN (S. S.)</s1>
</fA11>
<fA14 i1="01"><s1>Moortields Eye Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Tanta University Ophthalmology Hospital</s1>
<s2>Tanta</s2>
<s3>EGY</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Royal Prince Alfred Hospital</s1>
<s2>Sydney, New South Wales</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Whipps Cross University Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>916-921</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>1015</s2>
<s5>354000149408200220</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>36 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0303695</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>British journal of ophthalmology</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Aims: To examine the visual outcome and identify risk factors for postoperative uveitis, macular oedema and neodymium-doped yttrium aluminium garnet (Nd:YAG) capsulotomy after phacoemulsification and intraocular lens (IOL) implantation in patients with uveitis. Method: This is a retrospective review of the medical records of 101 eyes of 101 patients. One eye was randomly selected for inclusion in patients who had bilateral surgery. Patients with juvenile arthritis, keratouveitis and lymphoma-associated uveitis were excluded. Results: At the first postoperative and final visits, visual acuity was significantly better (p<0.001), and 64.4% and 71.3% of patients, respectively, had achieved ≥2 Snellen's lines of visual improvement. The cumulative probability of doubling of the visual angle was 52% over 6 years of follow-up, and this occurred at a higher rate in the presence of preoperative retinal or optic nerve lesions (HR (95% Cl) 4.49 (1.41 to 14.29)). Within 3 months after operation, uveitis was more likely to develop in female patients (OR (95% Cl) 6.21 (1.41 to 27.43)) and in the presence of significant intraoperative posterior synechiae (OR (95% Cl) 8.43 (1.09 to 65.41)); macular oedema was more likely to develop in patients who developed postoperative uveitis (OR (95% Cl) 7.45 (1.63 to 34.16)). Nd:YAG capsulotomy occurred at a higher rate in patients aged ≤5 years (HR (95% Cl) 2.28 (1.06, 4.93)) and in those with hydrogel lOLs (HR (95% Cl) 3.71 (1.04 to 13.20)), and occurred at a lower rate in patients who had prophylactic systemic corticosteroids (HR (95% Cl) 0.25 (0.11 to 0.59)), with plate-haptic silicone lOLs (HR (95% Cl) 0.23 (0.08 to 0.64)) and three-piece silicone lOLs (HR (95% Cl) 0.19 (0.05 to 0.74)) in comparison to those with polymethylmethacrylate lOLs. Conclusion: Most patients with uveitis achieve improved visual acuity after phacoemulsification, but an increasing rate of visual loss is observed in those with pre-existent macular or optic nerve lesions. Identifying patients who are at risk of postoperative complications should help in patient counselling and to pre-empt these complications by using preoperative prophylactic corticosteroids, careful IOL selection and postoperative intensive corticosteroids.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B09N</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B09F</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Uvéite</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Uveitis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Uveitis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Evolution</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Evolution</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Evolución</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Phacoémulsification</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Phacoemulsification</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Facoemulsificación</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Chirurgie</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Surgery</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Cirugía</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Human</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Ophtalmologie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Ophthalmology</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Oftalmología</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Traitement</s0>
<s5>25</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Treatment</s0>
<s5>25</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>25</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Oeil pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Eye disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Ojo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Uvée pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Uvea disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Uvea patología</s0>
<s5>38</s5>
</fC07>
<fN21><s1>197</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 07-0303695 INIST</NO>
<ET>Outcome of phacoemulsification in patients with uveitis</ET>
<AU>ELGOHARY (M. A.); MCCLUSKEY (P. J.); TOWLER (H. M. A.); OKHRAVI (N.); SINGH (R. P.); OBIKPO (R.); LIGHTMAN (S. S.)</AU>
<AF>Moortields Eye Hospital/London/Royaume-Uni (1 aut., 4 aut., 7 aut.); Tanta University Ophthalmology Hospital/Tanta/Egypte (1 aut.); Royal Prince Alfred Hospital/Sydney, New South Wales/Australie (2 aut., 5 aut.); Whipps Cross University Hospital/London/Royaume-Uni (3 aut., 6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>British journal of ophthalmology; ISSN 0007-1161; Coden BJOPAL; Royaume-Uni; Da. 2007; Vol. 91; No. 7; Pp. 916-921; Bibl. 36 ref.</SO>
<LA>Anglais</LA>
<EA>Aims: To examine the visual outcome and identify risk factors for postoperative uveitis, macular oedema and neodymium-doped yttrium aluminium garnet (Nd:YAG) capsulotomy after phacoemulsification and intraocular lens (IOL) implantation in patients with uveitis. Method: This is a retrospective review of the medical records of 101 eyes of 101 patients. One eye was randomly selected for inclusion in patients who had bilateral surgery. Patients with juvenile arthritis, keratouveitis and lymphoma-associated uveitis were excluded. Results: At the first postoperative and final visits, visual acuity was significantly better (p<0.001), and 64.4% and 71.3% of patients, respectively, had achieved ≥2 Snellen's lines of visual improvement. The cumulative probability of doubling of the visual angle was 52% over 6 years of follow-up, and this occurred at a higher rate in the presence of preoperative retinal or optic nerve lesions (HR (95% Cl) 4.49 (1.41 to 14.29)). Within 3 months after operation, uveitis was more likely to develop in female patients (OR (95% Cl) 6.21 (1.41 to 27.43)) and in the presence of significant intraoperative posterior synechiae (OR (95% Cl) 8.43 (1.09 to 65.41)); macular oedema was more likely to develop in patients who developed postoperative uveitis (OR (95% Cl) 7.45 (1.63 to 34.16)). Nd:YAG capsulotomy occurred at a higher rate in patients aged ≤5 years (HR (95% Cl) 2.28 (1.06, 4.93)) and in those with hydrogel lOLs (HR (95% Cl) 3.71 (1.04 to 13.20)), and occurred at a lower rate in patients who had prophylactic systemic corticosteroids (HR (95% Cl) 0.25 (0.11 to 0.59)), with plate-haptic silicone lOLs (HR (95% Cl) 0.23 (0.08 to 0.64)) and three-piece silicone lOLs (HR (95% Cl) 0.19 (0.05 to 0.74)) in comparison to those with polymethylmethacrylate lOLs. Conclusion: Most patients with uveitis achieve improved visual acuity after phacoemulsification, but an increasing rate of visual loss is observed in those with pre-existent macular or optic nerve lesions. Identifying patients who are at risk of postoperative complications should help in patient counselling and to pre-empt these complications by using preoperative prophylactic corticosteroids, careful IOL selection and postoperative intensive corticosteroids.</EA>
<CC>002B09N; 002B09F</CC>
<FD>Uvéite; Pronostic; Evolution; Phacoémulsification; Chirurgie; Homme; Ophtalmologie; Traitement</FD>
<FG>Oeil pathologie; Uvée pathologie</FG>
<ED>Uveitis; Prognosis; Evolution; Phacoemulsification; Surgery; Human; Ophthalmology; Treatment</ED>
<EG>Eye disease; Uvea disease</EG>
<SD>Uveitis; Pronóstico; Evolución; Facoemulsificación; Cirugía; Hombre; Oftalmología; Tratamiento</SD>
<LO>INIST-1015.354000149408200220</LO>
<ID>07-0303695</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Ticri/CIDE/explor/HapticV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B40 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000B40 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Ticri/CIDE
   |area=    HapticV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:07-0303695
   |texte=   Outcome of phacoemulsification in patients with uveitis
}}

This area was generated with Dilib version V0.6.23.
Data generation: Mon Jun 13 01:09:46 2016. Site generation: Wed Mar 6 09:54:07 2024

	Serveur d'exploration sur les dispositifs haptiques
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les dispositifs haptiques

Outcome of phacoemulsification in patients with uveitis

Outcome of phacoemulsification in patients with uveitis

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri